Financial Data and Key Metrics Changes - Research and development expenses decreased to $16.5 million for Q4 2025 from $20.3 million in Q4 2024, primarily due to strategic reprioritization and reduced costs associated with the pausing of the Revitalize-1 study [24] - SG&A expenses increased to $6.8 million for Q4 2025 from $4.9 million in Q4 2024, mainly due to underwriter's commissions related to financing [24] - The net loss for Q4 2025 was $43.7 million compared to $25 million in Q4 2024, with a significant portion of the increase attributed to a non-cash accounting change [25] - Adjusted EBITDA improved to -$21.2 million for Q4 2025 from -$22.1 million in Q4 2024, reflecting a decrease in operating expenses [25] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027 [25][26] Business Line Data and Key Metrics Changes - Revita is positioned as a solution for maintaining weight loss after GLP-1 therapy discontinuation, with a focus on a specific patient population that shows a strong treatment effect [4][20] - The pivotal study has enrolled over 300 participants across more than 30 sites, making it the largest sham-controlled GI endoscopy pivotal trial conducted [18] Market Data and Key Metrics Changes - The anticipated population on GLP-1 drugs is projected to exceed 30 million in the coming years, with over 50% expected to lose more than 17.5% of their total body weight [20] - The payer landscape is evolving, with expanded Medicare coverage of GLP-1s increasing the addressable patient population while also intensifying economic pressures on payers [20] Company Strategy and Development Direction - The company aims to submit a de novo classification request for Revita by late Q4 2026, with favorable FDA feedback received on the safety profile [19][20] - Revita is the first FDA breakthrough device designed for post GLP-1 weight maintenance, addressing a significant unmet need in the market [20] - The company plans to file a Category III CPT code application in summer 2026, with expectations for it to be effective by summer 2027 [21][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical signal of Revita, highlighting a strong dose-response relationship and a clear target population for treatment [28] - The pivotal study is designed to succeed with strong powering and an optimized cohort of patients, aiming for a positive outcome [28] - The company is committed to operating within its existing capital envelope until pivotal data is available, signaling alignment with shareholders [27][28] Other Important Information - The Rejuva program, targeting long-term metabolic remission from a single dose, is advancing with clinical trial applications submitted in the EU and Australia [22] - The company anticipates several key milestones in 2026, including pivotal data readouts and regulatory feedback [23] Q&A Session Summary Question: How is the ablation length determined? - Ablation length is calculated based on the total amount of duodenum ablated during the procedure, with a target minimum of 16 cm established for future procedures [31][33] Question: Does this impact how doctors will be trained in the future? - Physicians are trained to perform at least 10 cm of ablation, with the expectation that they can consistently achieve greater than 14 cm based on the data [34] Question: What is the role of efficacy in the de novo submission? - The de novo pathway determination is primarily a safety consideration, with efficacy being assessed as reasonable assurance of safety and effectiveness [39] Question: How long does it take to train physicians for the procedure? - Training takes less than three to four cases for physicians to perform adequate ablations, with consistency improving as they gain experience [56] Question: Will there be further analysis by length for the REMAIN-1 midpoint cohort? - Yes, further analysis by length will be provided in the upcoming data readouts [60] Question: What is the timeline for the CPT code filing? - The company plans to file for a Category III CPT code in June 2026, with an expected effective date in summer 2027 [62]

Financial Data and Key Metrics Changes - In 2025, Comstock's revenues were approximately $1.4 million, a decrease from $4.4 million in 2024, with additional billings of about $2.2 million classified as deferred revenue [8][9] - The company reported cash and cash equivalents of approximately $56 million as of March 20, 2026, following a successful equity offering that raised about $57.5 million in gross proceeds [4][5] Business Line Data and Key Metrics Changes - Comstock Metals generated revenues of approximately $1.4 million in 2025, down from $4.4 million in 2024, indicating a significant decline in operational performance [8] - The company is focusing on monetizing non-core assets, including legacy mining assets, to fund its growth in the metals recycling sector [17][19] Market Data and Key Metrics Changes - The U.S. has over 1.3 billion solar panels deployed, with a significant portion reaching end-of-life rapidly, presenting a substantial market opportunity for Comstock [12][29] - The company aims to capture a large share of the end-of-life solar panel recycling market, particularly in the Southwest region, which holds about 50% of this market [23][34] Company Strategy and Development Direction - Comstock is positioning itself as a leader in the metals recycling industry, with plans to establish multiple recycling facilities across the U.S. and a central refinery hub [68] - The company is actively engaging with institutional investors and enhancing its governance structure to support its growth objectives [10][11] - The strategy includes monetizing non-core legacy mining assets and real estate to fund the expansion of its recycling operations [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong position and liquidity, anticipating significant revenue growth from metals recycling in 2026 [9][28] - The CEO highlighted the importance of securing strategic partnerships and customer agreements to ensure a steady flow of recyclable materials [56][60] - The company is optimistic about the demand for silver and other metals, projecting substantial cash flow from its recycling operations [29][36] Other Important Information - Comstock completed an oversubscribed equity offering, which significantly changed its shareholder base and provided necessary capital for growth [5][10] - The company is in the process of establishing additional permitted storage sites in states like California, Ohio, and Texas to support its operations [6][27] Q&A Session Summary Question: How do you allocate your time, versus Judd's time, versus the rest of the team's time? - Management allocates approximately 40%-50% of their time to monetizing non-core assets, while the metals team dedicates 110% of their time to metals operations [54] Question: What is the pipeline of solar panels that will be available to recycle through the Silver Springs facility once it is open? - The company is signing master service agreements with major utilities and e-recyclers, aiming for a significant market share in the recycling of end-of-life solar panels [56][59] Question: Where do we stand with the delivery of the first recycling facility in terms of timing and cost? - All equipment for the first recycling facility has been received, with installation and testing underway, aiming for operational status in Q2 2026 [63][64] Question: Please review the timetable for the second recycling project and its initial revenue and probable location. - The second facility will be located outside of Las Vegas, with permits submitted and equipment orders expected to be placed soon to expedite the timeline [66][68]

Financial Data and Key Metrics Changes - Revenue for the fourth quarter was $700,000, with research and development expenses increasing to $25.3 million from $18.4 million year-over-year, primarily due to advancements in internal programs [26][27] - Selling, general, and administrative expenses were $8.6 million, slightly down from $8.8 million in the prior year [26] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $144.3 million, down from $152.5 million as of September 30, 2025 [27] Business Line Data and Key Metrics Changes - The company is advancing its lead program, ABS-201, for androgenetic alopecia (AGA) and endometriosis, with ongoing clinical trials showing favorable safety data [7][19] - ABS-201 is designed to provide durable hair regrowth with a convenient dosing regimen, potentially requiring only two to three administrations over a six-month period [10][11] Market Data and Key Metrics Changes - The total addressable market for ABS-201 in the U.S. for AGA is estimated at approximately 15-18 million consumers, with potential annual treatable patient volume ranging from 5-9 million [22][23] - The market for endometriosis is also significant, with an estimated 10% of women of reproductive age affected globally, and no FDA-approved disease-modifying therapy currently available [12][14] Company Strategy and Development Direction - The company aims to target underexplored areas in large markets with significant unmet needs and low competition, focusing resources on ABS-201 while seeking partnerships for other programs [13][14] - The strategy includes leveraging the generative AI platform, Origin-1, for efficient drug design and development, which has shown to reduce time and costs compared to industry standards [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical momentum and the ability to reach proof of concept for both AGA and endometriosis, with key data readouts expected in 2026 and 2027 [29] - The company is well-positioned financially to support ongoing operations and clinical trials into the first half of 2028 [27][28] Other Important Information - The company has expanded its advisory networks for both AGA and endometriosis, enhancing trial design and endpoint selection [9] - The engagement with patients and advocacy groups has reinforced the need for better treatment options in endometriosis, which has been underserved for decades [11][12] Q&A Session Summary Question: What should investors look for in terms of ABS-201's target product profile? - Management aims for ABS-201 to achieve durable treatment and efficacy at or above minoxidil levels, with a target of 35-40 hairs per square centimeter [31][34] Question: Can you elaborate on the safety profile observed in the SAD portion of the trial? - Early data shows no evidence of on-target or off-target safety signals, which is encouraging [39][40] Question: How do you envision ABS-201 being used in relation to other agents like clascoterone? - Management sees ABS-201 as a synergistic option that could provide durable hair regrowth with fewer doses compared to daily treatments [68][70] Question: What are the expected challenges in developing a drug for endometriosis? - Pain studies require careful consideration in site selection and protocol design to mitigate placebo effects [84] Question: How should resource allocation be viewed between AGA and endometriosis? - Both programs are seen as significant opportunities, with a streamlined development path allowing for efficient resource allocation [85]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased 18% year-over-year to $20.9 million, and full-year revenue grew 16% to $80.3 million [24] - OviTex revenue grew 12% and OviTex PRS grew 20% for the year, with OviTex unit sales increasing 20% for the quarter and 22% for the year [24] - Gross margin improved to 66% for Q4 and 68% for the full year, compared to 64% and 67% in the prior year periods [25] - Net loss was $9 million in Q4 and $38.8 million for the full year, compared to $9.2 million and $37.8 million in the prior year periods [27] Business Line Data and Key Metrics Changes - LiquiFix revenue more than tripled over Q4 2024, indicating early commercial traction [24] - European sales accounted for 15% of total revenue, increasing 17% from $10.3 million in 2024 to $12.1 million in 2025 [25] - Sales and marketing expenses were $14.5 million in Q4 and $63.2 million for the full year, reflecting increased commissions due to stronger revenue [26] Market Data and Key Metrics Changes - The U.S. commercial organization underwent significant changes, with a focus on improving talent and processes to drive growth [5][7] - The company is seeing strong demand in hernia repair and plastic reconstructive surgery markets, with no signs of diminished opportunity [5] Company Strategy and Development Direction - The company aims to sustain momentum from 2025 and achieve further sales growth in the U.S. and Europe through improved talent and commercial leadership [7] - A focus on product innovation is central to the company's strategy, with plans for additional product launches throughout the year [8] - The company is investing in expanding its presence in continental Europe, viewing it as a meaningful contributor to future growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new commercial foundation and the potential for sustained growth, despite the challenges of integrating new sales reps [12][22] - The company anticipates revenue growth of at least 8% over 2025, with Q1 2026 revenue expected to be approximately $18.5 million [28] - Management acknowledged the complexities of contract execution and the need for time to mature the new sales team [40][41] Other Important Information - The company launched OviTex LTR, a new product offering, and enrolled patients in a hiatal hernia trial to strengthen clinical evidence [10] - The company has upgraded its board of directors to include new expertise [11] Q&A Session Summary Question: Guidance for fiscal year top line growth - Management explained the cautious guidance of at least 8% growth due to the significant changes in the organization and the need for new reps to mature [36][38] Question: Contracting and execution expectations - Management highlighted the focus on executing existing contracts and the complexity involved in the contracting process [48][49] Question: Q1 guidance and external factors - Management noted that Q1 performance was impacted by external factors such as weather and market conditions, but emphasized the focus on controllable factors like hiring and training [87][88] Question: Long-term growth outlook - Management expressed confidence in returning to double-digit growth rates once the organization stabilizes and new products are launched [62][63]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $33 million, a 15% decline from $38.6 million in 2024 [23] - Fourth quarter revenue for 2025 was $7.3 million, down 16% from $8.7 million in Q4 2024 [23] - Core revenue for 2025 was $29.6 million, a 9% decrease from $32.5 million in 2024 [24] - Gross margin in Q4 2025 was 78%, up from 74% in Q4 2024 [26] - Total operating expenses for Q4 2025 were $16.9 million, down from $19.3 million in Q4 2024 [27] Business Line Data and Key Metrics Changes - Instrument revenue for Q4 2025 was $1.8 million, compared to $1.6 million in Q4 2024 [24] - License revenue in Q4 2025 was $2 million, down from $2.6 million in Q4 2024 [24] - PA revenue in Q4 2025 was $2.3 million, compared to $4.2 million in Q4 2024 [24] - SPL program-related revenue for 2025 was $3.4 million, down from $6.1 million in 2024 [26] Market Data and Key Metrics Changes - 47% of core business revenue was derived from SPL customers in 2025, down from 55% in 2024 [25] - The company supports 12 clinical programs across 11 SPL partners, with 5 programs expected to enter pivotal studies over the next 18 months [14][16] Company Strategy and Development Direction - The company launched the ExPERT DTx platform, aimed at enhancing early-stage research and drug discovery [6][8] - The company expects to stabilize and grow its SPL customer base despite recent headwinds [10] - The company is focused on innovation and maintaining a competitive edge in the market [10][18] Management's Comments on Operating Environment and Future Outlook - Management indicated that the challenges faced in 2025 will impact the first half of 2026, with a revenue guidance of $30 million-$32 million for 2026 [9] - Management remains optimistic about the medium-term opportunities, with multiple clinical programs progressing towards commercialization [14][18] - The company has reduced annual cash burn by over $16 million and is on a different spending trajectory [21] Other Important Information - The company ended 2025 with a strong balance sheet, having $155.6 million in cash and no debt [28] - A new CFO, Parmeet Ahuja, will join the company effective March 30 [22] Q&A Session Summary Question: Concerns about business trajectory and core revenue decline - Management clarified that the expected decline in core revenue is due to a $4 million headwind from lost customers, not a deterioration in business fundamentals [31][32] Question: Outlook for core revenues and industry demand - Management indicated that any improvement in industry demand would be upside to the current guidance, which is not contingent on external factors [36] Question: Pipeline and revenue contribution from the DTx platform - Management expects revenue from the DTx platform to begin trickling in during the second half of 2026, with significant contributions anticipated in 2027 [41][42] Question: SPL signing cadence and visibility - Management expressed confidence in signing at least three new SPLs in 2026, with ongoing discussions with potential partners [50][51] Question: SeQure contribution and royalty revenue visibility - Management expects significant year-over-year growth from SeQure Dx in 2026, with approximately $2 million in expected royalty revenue [60]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $33 million, a 15% decline from $38.6 million in 2024. Fourth quarter revenue was $7.3 million, down 16% from $8.7 million in Q4 2024 [23][24]. - Core revenue for 2025 was $29.6 million, a 9% decrease from $32.5 million in 2024. In Q4 2025, core revenue was $6.8 million, down 22% from $8.6 million in Q4 2024 [24][25]. - Gross margin was 78% in Q4 2025, up from 74% in Q4 2024, but non-GAAP adjusted gross margin decreased to 78% from 84% year-over-year [26]. Business Line Data and Key Metrics Changes - Instrument revenue for 2025 was $6.8 million, down from $7.1 million in 2024. License revenue decreased to $8.9 million from $10.3 million, and PA revenue fell to $11.9 million from $14 million [24][25]. - SPL program-related revenue was $3.4 million in 2025, down from $6.1 million in 2024, with $2.3 million from milestone payments and $1.2 million from royalties [25][26]. Market Data and Key Metrics Changes - 47% of core business revenue was derived from SPL customers in 2025, compared to 55% in 2024, reflecting the impact of program exits and reduced purchasing activity [25]. - The company supports 12 clinical programs across 11 SPL partners, with 5 programs expected to enter pivotal studies over the next 18 months [14][16]. Company Strategy and Development Direction - The company launched the ExPERT DTx platform, a modular 96-well electroporation platform aimed at enhancing research and drug discovery applications [6][8]. - The company aims to stabilize and grow its SPL customer base, despite short-term headwinds, and is optimistic about the medium-term opportunities from clinical programs [10][12]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the challenges faced in 2025 would impact the first half of 2026, with guidance for total revenue in 2026 expected to be between $30 million and $32 million [9][10]. - Management expressed confidence in the demand for their technology and the potential for growth, citing ongoing advancements in clinical programs and the launch of new products [10][18]. Other Important Information - The company ended 2025 with a strong balance sheet, reporting $155.6 million in cash and cash equivalents, with no debt [27][28]. - A new CFO, Parmeet Ahuja, will join the company effective March 30, bringing extensive finance leadership experience [22][23]. Q&A Session Questions and Answers Question: Concerns about the trajectory of the business - Management clarified that the expected decline in core business revenue is due to a $4 million headwind from lost customers, not a deterioration in business fundamentals [31][32]. Question: Outlook for core revenues and industry demand - Management indicated that the current guidance does not rely on improvements in industry demand, and any such improvements would be considered upside [36]. Question: Contribution of SeQure Dx to revenue - Management expects significant year-over-year growth for SeQure Dx in 2026, following integration efforts [60]. Question: Customer appetite for ex vivo edits - Management remains optimistic about the ex vivo cell therapy space and believes that increasing complexity in therapies will drive demand for their technology [65].

Financial Data and Key Metrics Changes - In Q4, the company generated $205 million in revenue, representing a 28% year-over-year increase and an 8% increase from the prior quarter [7] - For the full fiscal year 2026, the company achieved 24% year-over-year revenue growth and $28 million in non-GAAP operating income, with operating margins expanding nearly 400 basis points [8] - Non-GAAP net income for FY 2026 was $42 million, up from $18 million the previous year, and free cash flow was $58 million [9] - The dollar-based net retention rate improved to 109%, up from 108% in the previous quarter [25] Business Line Data and Key Metrics Changes - BrazeAI Decisioning Studio contributed $5.7 million in revenue during Q4, indicating strong demand for AI products [23] - The total customer count increased by 14% year-over-year to 2,609 customers, with large customers (spending at least $500,000 annually) growing by 35% year-over-year to 333 [24] - The company signed 29 deals exceeding $500,000 in Q4, including seven deals over $1 million [10] Market Data and Key Metrics Changes - Revenue outside the U.S. accounted for 45% of total revenue in Q4, consistent with previous quarters [25] - The total remaining performance obligation was over $1 billion, up 30% year-over-year and 16% sequentially [25] Company Strategy and Development Direction - The company is focused on leveraging AI to enhance customer engagement and drive growth, with a strong emphasis on product innovation and market expansion [21] - The management highlighted the importance of a tightly integrated infrastructure that combines context and intelligence layers to support customer engagement [44] - The company plans to continue investing in AI capabilities and expanding its global customer community to enhance marketing programs and customer experiences [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong demand for AI-driven solutions and a robust product roadmap [36] - The company anticipates continued momentum in the enterprise market and expects to capitalize on the growing demand for customer engagement solutions [12] - Management noted that the competitive landscape is shifting, with brands increasingly migrating from legacy platforms to Braze [11] Other Important Information - The company announced a $100 million share repurchase authorization, reflecting confidence in its fundamentals and outlook [30] - The guidance for Q1 FY 2027 includes expected revenue in the range of $204.5 million to $205.5 million, representing approximately 26% year-over-year growth [31] - For the full fiscal year 2027, the company expects total revenue between $884 million and $889 million, indicating a year-over-year growth rate of approximately 20% [32] Q&A Session Summary Question: What is the underlying growth trajectory of Braze? - Management indicated that the differentiation of the AI roadmap and strong product delivery have positively impacted win rates and deal velocity [36] Question: Can you discuss the guidance philosophy and key points for the full year guide? - Management confirmed no change in guidance philosophy, citing momentum in the business, larger contract sizes, and ongoing strength in the enterprise [39] Question: What are the challenges in replacing Braze's platform? - Management highlighted the complexity of customer journeys and the need for a tightly integrated infrastructure as key challenges for customers attempting to replace Braze [44] Question: How does Braze benefit from new consumer interfaces? - Management stated that Braze will invest in new consumer interfaces to better understand customer journeys and enhance personalization [49] Question: Can you elaborate on the dollar-based net retention improvement? - Management noted that the in-quarter organic number is above reported figures, indicating positive momentum in the business [56]

Financial Data and Key Metrics Changes - Research and development expenses decreased to $16.5 million for Q4 2025 from $20.3 million in Q4 2024, primarily due to strategic reprioritization and reduced costs associated with the pausing of the Revitalize One study [24] - SG&A expenses increased to $6.8 million for Q4 2025 from $4.9 million in Q4 2024, mainly due to underwriter's commissions from financing [24] - The net loss for Q4 2025 was $43.7 million compared to $25 million in Q4 2024, with a significant portion of the increase attributed to a non-cash accounting change [25] - Adjusted EBITDA improved to negative $21.2 million for Q4 2025 from negative $22.1 million in Q4 2024, reflecting a decrease in operating expenses [25] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027 [25][26] Business Line Data and Key Metrics Changes - Revita, the lead asset, is positioned as a solution for maintaining weight loss after GLP-1 therapy discontinuation, with a focus on a pivotal study designed to validate its efficacy [4][5] - The pivotal study has enrolled over 300 participants across more than 30 sites, making it the largest sham-controlled GI endoscopy pivotal trial conducted [18] Market Data and Key Metrics Changes - The anticipated population on GLP-1 drugs is projected to exceed 30 million users in the coming years, with over 50% expected to lose more than 17.5% of their total body weight [20] - The payer landscape is evolving, with expanded Medicare coverage of GLP-1s increasing the addressable patient population and intensifying economic pressures on payers [20] Company Strategy and Development Direction - The company aims to submit a de novo classification request for Revita by late Q4 2026, with favorable FDA feedback received on its safety profile [19] - Revita is positioned as the first FDA breakthrough device designed for post GLP-1 weight maintenance, addressing a significant unmet need in the market [20] - The company plans to file a Category III CPT code application in summer 2026, with expectations for effective reimbursement by summer 2027 [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical signal of Revita, highlighting a strong dose-response relationship and a well-structured pivotal study [28] - The company is committed to operating within its existing capital envelope without planned incremental capital raises before pivotal data is available [27][28] - Management anticipates delivering top-line six-month primary endpoint data in early Q4 2026, which is considered a critical milestone for the company [24][28] Other Important Information - The Rejuva program, targeting long-term metabolic remission from a single dose, is advancing with clinical trial applications submitted in the EU and Australia [22] - The company is preparing for a potential commercial launch of Revita, with a clear and validated pathway for reimbursement [21][22] Q&A Session Summary Question: How is the ablation length determined? - Ablation length is calculated based on the total amount of duodenum ablated during the procedure, with a target minimum of 16 centimeters established for future studies [31][33] Question: Does this impact physician training for ablation length? - Physicians were advised to aim for at least 10 centimeters of ablation, with training allowing them to consistently achieve greater than 14 centimeters [34] Question: What is the role of efficacy in the de novo submission? - The de novo pathway primarily considers safety, with efficacy being a secondary factor compared to PMA submissions [39] Question: Is 16 centimeters of ablation readily achievable in the average patient? - In the pivotal cohort, the mean and median ablation length exceeded 16 centimeters, which is considered achievable by trained investigators [41] Question: How long does it take to train physicians for the procedure? - Training typically requires less than 3-4 cases for physicians to perform adequate ablations [56]

Financial Data and Key Metrics Changes - In Q4, the company generated $205 million in revenue, representing a 28% year-over-year increase and an 8% increase from the prior quarter [7] - For the full fiscal year 2026, the company achieved 24% year-over-year revenue growth and $28 million in non-GAAP operating income, with operating margins expanding nearly 400 basis points [8] - Non-GAAP net income for FY 2026 was $42 million, up from $18 million the previous year, and free cash flow was $58 million [9] - The dollar-based net retention rate improved to 109%, up from 108% in the previous quarter [25] Business Line Data and Key Metrics Changes - BrazeAI Decisioning Studio contributed $5.7 million in revenue during Q4, indicating strong demand for AI products [23] - The total customer count increased by 14% year-over-year to 2,609 customers, with large customers (spending at least $500,000 annually) growing by 35% year-over-year to 333 [24] - The company signed 29 deals exceeding $500,000 in Q4, including seven deals over $1 million [10] Market Data and Key Metrics Changes - Revenue outside the U.S. accounted for 45% of total revenue in Q4, consistent with previous quarters [25] - The total remaining performance obligation was over $1 billion, up 30% year-over-year and 16% sequentially [25] Company Strategy and Development Direction - The company is focused on leveraging AI to enhance customer engagement and drive growth, with a strong emphasis on product innovation and market expansion [21] - The management highlighted the importance of a tightly integrated infrastructure that combines context and intelligence layers to enhance customer journeys [44] - The company plans to continue investing in AI capabilities and expanding its global customer community to capitalize on market opportunities [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong demand for AI-driven solutions and a robust product roadmap [36] - The company anticipates continued momentum in the enterprise sector and expects to see improvements in sales productivity under the new Chief Revenue Officer [12][39] - Management noted that the competitive landscape is shifting in favor of Braze due to its AI-driven omni-channel approach [11] Other Important Information - The company announced a $100 million share repurchase program, reflecting confidence in its long-term growth potential [30] - The guidance for Q1 FY 2027 includes expected revenue of $204.5 million to $205.5 million, representing a year-over-year growth rate of approximately 26% [31] - For the full fiscal year 2027, the company expects total revenue in the range of $884 million to $889 million, indicating a year-over-year growth rate of approximately 20% [32] Q&A Session Summary Question: What is the underlying growth trajectory of Braze? - Management indicated that the differentiation of the AI roadmap and strong product delivery have positively impacted win rates and deal velocity [36] Question: Is there any change in the guidance philosophy for the full year? - Management confirmed no change in guidance philosophy, citing strong momentum and larger contract sizes as key factors in the guidance [39] Question: What are the challenges in replacing Braze with custom solutions? - Management highlighted the complexity of integrating high-performance infrastructure and the need for comprehensive solutions to manage customer journeys effectively [44] Question: How does Braze benefit from new consumer interfaces? - Management stated that Braze will invest in new consumer interfaces to enhance customer understanding and drive better personalization [49] Question: What is the outlook for dollar-based net retention? - Management expressed optimism about the upward trend in dollar-based net retention, indicating that the company is through previous challenges [56] Question: What is the impact of premium messaging on gross margins? - Management noted that while premium messaging channels are in demand, the impact on gross margins will take time to materialize [64] Question: How is AI making existing capabilities more accessible? - Management provided examples of how AI innovations are enhancing usability and driving higher performance in existing customer journeys [66]

Financial Data and Key Metrics Changes - In 2025, Comstock doubled its asset base and strengthened its balance sheet by eliminating legacy debt and obligations, positioning the company for growth [3][4] - Cash and cash equivalents were approximately $56 million as of March 20, 2026, with common shares outstanding at 74 million [4] - Revenues for Comstock Metals in 2025 were approximately $1.4 million, down from $4.4 million in 2024, with additional billings of about $2.2 million [8][9] Business Line Data and Key Metrics Changes - Comstock Metals generated revenues of approximately $1.4 million in 2025, a decrease from $4.4 million in 2024, with deferred revenue totaling about $3.5 million for the year [8][9] - The company is focusing on monetizing non-core assets, including legacy mining assets and real estate, to fund its solar recycling business [17][19] Market Data and Key Metrics Changes - The U.S. has over 1.3 billion solar panels deployed, with a significant portion reaching end-of-life rapidly, creating a substantial market opportunity for recycling [12][60] - The company is engaged with major utilities and e-recyclers to secure contracts for recycling services, targeting 80% of the market [56][57] Company Strategy and Development Direction - Comstock aims to become a dominant player in the metal recycling industry, with plans to monetize non-core assets to fund growth in solar recycling [17][19] - The company is expanding its governance structure by adding experienced independent directors to enhance its operational capabilities [13][14] - Plans include deploying a second industry-scale metals recycling facility in Clark County, Nevada, to capture market share in the Southwest [27][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to capitalize on the growing demand for solar panel recycling, with expectations of significant revenue growth in 2026 [28][29] - The company anticipates that its first recycling facility will be operational in Q2 2026, with a projected revenue increase from $100,000 to $2 million per month [28][62] Other Important Information - Comstock completed a second oversubscribed equity offering, raising approximately $57.5 million in gross proceeds, which will support its growth initiatives [5][6] - The company is actively seeking non-dilutive funding sources, including grants and industrial bonds, to further strengthen its financial position [9] Q&A Session Summary Question: How do you allocate your time, versus Judd's time, versus the rest of the team's time? - Management allocates approximately 40%-50% of their time to monetizing non-core assets, while the metals team dedicates 110% of their time to metals operations [54] Question: What is the pipeline of solar panels that will be available to recycle through the Silver Springs facility once it is open? - The company is signing master service agreements with major utilities and e-recyclers, targeting a revenue run rate of $24 million-$25 million by the end of 2027 [56][59] Question: Where do we stand with the delivery of the first recycling facility in terms of timing and cost? - All equipment for the first facility has been received, with installation and testing underway, aiming for operational status in Q2 2026 [62][63] Question: Please review the timetable for the second recycling project. - The second facility will be located outside of Las Vegas, with permits submitted and equipment orders expected to be placed soon [66]